Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | BCAX | Common Stock | Conversion of derivative security | $0 | +4.33M | +3738.32% | $0.00 | 4.44M | Sep 16, 2024 | By Biocon Limited | F1, F2 |
transaction | BCAX | Common Stock | Conversion of derivative security | $0 | +1.08M | $0.00 | 1.08M | Sep 16, 2024 | By Biocon Pharma Inc. | F1, F3 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | BCAX | Series Seed Redeemable Convertible Preferred Stock | Conversion of derivative security | $0 | -40M | -100% | $0.00 | 0 | Sep 16, 2024 | Common Stock | 4.33M | By Biocon Limited | F1, F2 | |
transaction | BCAX | Series Seed Redeemable Convertible Preferred Stock | Conversion of derivative security | $0 | -9.99M | -100% | $0.00 | 0 | Sep 16, 2024 | Common Stock | 1.08M | By Biocon Pharma Inc. | F1, F3 |
Id | Content |
---|---|
F1 | Upon the closing of the Issuer's initial public offering, each share of Series Seed Redeemable Convertible Preferred Stock (the "Preferred Stock") automatically converted into Common Stock on a 9.2435-to-one basis without payment of consideration. The Preferred Stock had no expiration date. |
F2 | Shares held by Biocon Limited ("Biocon Ltd"). Kiran Mazumdar-Shaw is the managing member of Biocon Ltd. Each of the Reporting Persons and Ms. Mazumdar-Shaw disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any Reporting Person is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. |
F3 | Shares held by Biocon Pharma Inc. ("Biocon Pharma"). Kiran Mazumdar-Shaw is the managing member of Biocon Pharma. Each of the Reporting Persons and Ms. Mazumdar-Shaw disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any Reporting Person is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. |